AML-432 Overall Survival (OS) by Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant- Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial
Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Maroof Hasan(Bristol-Myers Squibb (United States)), Amir T. Fathi(University of Southern California), Lilia Taningco(Bristol-Myers Squibb (United States)), Stéphane de Botton(Université Paris-Saclay), Patricia Martin‐Regueira(Bristol-Myers Squibb (United States)), Wendy L. See(Bristol-Myers Squibb (United States)), Andre C. Schuh(University of Toronto), Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Paresh Vyas(University of Oxford), Alberto Risueño, Iryna Bluemmert(Bristol-Myers Squibb (United States)), Hartmut Döhner(University Hospital Ulm), Xin Yu(Shanghai Clinical Research Center), Hee‐Je Kim(St. Mary's Hospital), Bob Löwenberg(Unknown), Andrew H. Wei(The Royal Melbourne Hospital)
Cited by 0
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k